Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ablative Radiotherapy +/- Durvalumab for Early-Stage NSCLC
NCT03148327Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2017
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Treatment-related adverse events at 4 months and Progression-Free Survival at 2 years. Started Oct 2017; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03148327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148327.